Patient with HR-proficient advanced ovarian cancer achieved a complete response with Cadonilimab combined chemotherapy (PD-1/CTLA-4 bispecific): a case report and literature review

Objectives: For advanced ovarian cancer (OC), particularly OC with HR-deficient, surgery combined with adjuvant chemotherapy and maintenance therapy with PARPi/bevacizumab is the standard effective first-line treatment regimen. However, the clinical benefit of therapy for HR-proficient advanced OC i...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Gynecologic Oncology Reports
المؤلفون الرئيسيون:	Chenge Zhang, Miao Dai, Jun Yang, Wenfang Tian, Si Huang, Feng Bi, Kai Zheng, Jie Tang
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2025-08-01
الموضوعات:	Advanced ovarian cancer AK104/Cadonilimab PD-1/CTLA-4 bispecific antibody Complete response HR-proficient
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2352578925001109